Stem Cell Clinical Trials

166 recruitingLast updated: May 21, 2026

There are 166 actively recruiting stem cell clinical trials across 29 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include Boston, Massachusetts, United States, Beijing, Beijing Municipality, China, Suzhou, Jiangsu, China. Updated daily from ClinicalTrials.gov.


Stem Cell Trials at a Glance

166 actively recruiting trials for stem cell are listed on ClinicalTrialsFinder across 6 cities in 29 countries. The largest study group is Phase 2 with 56 trials, with the heaviest enrollment activity in Boston, Beijing, and Suzhou. Lead sponsors running stem cell studies include The First Affiliated Hospital of Soochow University, Peking University People's Hospital, and Children's Hospital Medical Center, Cincinnati.

About Stem Cell Clinical Trials

Looking for clinical trials for Stem Cell? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Stem Cell trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Stem Cell clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 166 trials

Recruiting
Phase 1Phase 2

Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

Sickle Cell DiseaseGraft FailureHematopoetic Stem Cell Transplant+2 more
University of Colorado, Denver24 enrolled4 locationsNCT07252050
Recruiting
Phase 2Phase 3

VABu Conditioning in Elderly AML HSCT

Acute Myeloid Leukemia (AML)Allogeneic Hematopoietic Stem Cell Transplantation Recipient
The First Affiliated Hospital of Soochow University20 enrolled1 locationNCT07583888
Recruiting
Phase 2

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854
Recruiting

Long-Term Follow-up of People Undergoing Hematopoietic Stem Cell Transplantation

Hematopoietic Stem Cell TransplantationTissue Donors
National Cancer Institute (NCI)2,000 enrolled1 locationNCT03000244
Recruiting
Phase 2

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Hematopoietic Stem Cell TransplantationImmunodeficiency
National Cancer Institute (NCI)54 enrolled1 locationNCT05027945
Recruiting
Phase 2

Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Acute Graft Versus Host DiseaseGraft-Versus-Host DiseaseALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology42 enrolled1 locationNCT07572669
Recruiting

Longitudinal Cohort Study on Invasive Fungal Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Invasive Fungal DiseaseAllogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Peking University People's Hospital6,000 enrolled1 locationNCT07569055
Recruiting
Not Applicable

Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation

Hematopoietic Stem Cell Transplant
University of Michigan Rogel Cancer Center10 enrolled1 locationNCT05945121
Recruiting
Phase 4

Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationCytomegalovirus Infections+1 more
WeiShi120 enrolled1 locationNCT07569653
Recruiting
Early Phase 1

Secretome Treatment for Facial Rejuvenation

Stem CellFacial AgingRejuvenation+1 more
Acorn Biolabs Inc.24 enrolled1 locationNCT07227883
Recruiting
Phase 2

Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

Sickle Cell DiseaseStem Cell Transplant ComplicationsPure Red Cell Aplasia+1 more
University of Calgary12 enrolled1 locationNCT03214354
Recruiting
Phase 1

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

Limbal Stem Cell Deficiency
Claris Biotherapeutics, Inc.75 enrolled6 locationsNCT06452316
Recruiting

Oral, Chemosensory and Trigeminal Functions in Allo-HSCT

Hematopoietic Stem Cell Transplantation
University of Oslo70 enrolled1 locationNCT06003660
Recruiting

A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT

Acute LeukemiaMenin InhibitorsPost Hematopoietic Stem Cell Transplantation+4 more
The First Affiliated Hospital of Soochow University20 enrolled1 locationNCT07559695
Recruiting
Phase 2

Ivosidenib as Post-HSCT Maintenance for AML

Acute Myeloid Leukemia (AML)IDH1 MutationHematopoietic Stem Cell Transplant (HSCT)
Massachusetts General Hospital75 enrolled4 locationsNCT06707493
Recruiting
Phase 1Phase 2

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Hematopoietic Stem Cell TransplantationPeripheral Blood Stem Cell Transplantation
National Cancer Institute (NCI)260 enrolled2 locationsNCT05436418
Recruiting

Treosulfan Therapeutic Drug Monitoring in Pediatric Hematopoietic Stem Cell Transplant Recipients

Non-malignant DisordersPediatric Hematopoietic Stem Cell TransplantationMalignant Disorders
Fondazione IRCCS Policlinico San Matteo di Pavia70 enrolled10 locationsNCT06861257
Recruiting
Phase 2

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

Hematologic MalignanciesHematopoietic Stem Cell Transplant (HSCT)
Pulmotect, Inc.100 enrolled11 locationsNCT06665100
Recruiting
Phase 2

Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen

Peripheral Blood Stem Cell Transplantation
Chinese PLA General Hospital50 enrolled1 locationNCT05088226
Recruiting

Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation.

Liver DiseasesHematopoietic Stem Cell Transplantation (HSCT)Iron Overload+1 more
Assistance Publique - Hôpitaux de Paris500 enrolled1 locationNCT07028112